Dexamethasone; Tobramycin Patent Expiration
Dexamethasone; Tobramycin is Used for treating ocular inflammation with infection or risk of infection using a combination of tobramycin and dexamethasone. It was first introduced by Sandoz Inc
Dexamethasone; Tobramycin Patents
Given below is the list of patents protecting Dexamethasone; Tobramycin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tobradex St | US7795316 | Topical ophthalmic compositions containing tobramycin and dexamethasone | Aug 03, 2028 | Harrow Eye |
| Tobradex St | US8101582 | Topical ophthalmic compositions containing tobramycin and dexamethasone | Dec 19, 2027 | Harrow Eye |
| Tobradex St | US8450287 | Topical ophthalmic compositions containing tobramycin and dexamethasone | Dec 19, 2027 | Harrow Eye |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dexamethasone; Tobramycin's patents.
Latest Legal Activities on Dexamethasone; Tobramycin's Patents
Given below is the list recent legal activities going on the following patents of Dexamethasone; Tobramycin.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 09 Jun, 2024 | US8450287 |
| Email Notification | 12 Dec, 2023 | US8450287 |
| Change in Power of Attorney (May Include Associate POA) | 12 Dec, 2023 | US8101582 |
| Email Notification | 12 Dec, 2023 | US7795316 |
| Change in Power of Attorney (May Include Associate POA) | 12 Dec, 2023 | US8450287 |
| Email Notification | 12 Dec, 2023 | US8101582 |
| Change in Power of Attorney (May Include Associate POA) | 12 Dec, 2023 | US7795316 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 24 Jan, 2023 | US8101582 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 14 Sep, 2021 | US7795316 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 12 Aug, 2020 | US8450287 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Dexamethasone; Tobramycin Generics
Several generic applications have been filed for Dexamethasone; Tobramycin. The first generic version for Dexamethasone; Tobramycin was by Bausch And Lomb Pharmaceuticals Inc and was approved on Oct 27, 1999. And the latest generic version is by Padagis Us Llc and was approved on Feb 11, 2022.
Given below is the list of companies who have filed for Dexamethasone; Tobramycin generic.
1. PADAGIS US
Padagis Us Llc has filed for 1 generic for Dexamethasone; Tobramycin. This 0.1%;0.3% version comes by the name TOBRAMYCIN AND DEXAMETHASONE. Given below are the details of the strengths of this generic introduced by Padagis Us.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1%; 0.3% | suspension/drops | Prescription | OPHTHALMIC | AB | Feb 11, 2022 |
2. BAUSCH AND LOMB
Bausch And Lomb Pharmaceuticals Inc has filed for 1 generic for Dexamethasone; Tobramycin. This 0.1%;0.3% version comes by the name TOBRAMYCIN AND DEXAMETHASONE. Given below are the details of the strengths of this generic introduced by Bausch And Lomb.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1%; 0.3% | suspension/drops | Prescription | OPHTHALMIC | AB | Oct 27, 1999 |
3. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Dexamethasone; Tobramycin. This 0.1%;0.3% version comes by the name TOBRAMYCIN AND DEXAMETHASONE. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1%; 0.3% | suspension/drops | Discontinued | OPHTHALMIC | N/A | Jul 15, 2021 |